Evidence map›Paper›PMID 42822365›Full record

ArticleClinics (Sao Paulo, Brazil)2026

Therapy dose, recovery phase, and patient factors influencing language outcomes in post-stroke aphasia.

Laura Carbonero Sancho, Olalla Saiz-Vázquez, Juan Hilario Ortiz-Huerta, Montserrat Santamaría-Vázquez

Abstract read
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Laura Carbonero SanchoUniversidad de Burgos, Health Sciences Department, España.
Olalla Saiz-VázquezUniversidad de Burgos, Health Sciences Department, España. Electronic address: osaiz@ubu.es.
Juan Hilario Ortiz-HuertaUniversidad de Burgos, Health Sciences Department, España.
Montserrat Santamaría-VázquezUniversidad de Burgos, Health Sciences Department, España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTherapy dose is increasingly recognized as an important factor influencing language recovery in post-stroke aphasia, yet evidence from routine clinical practice remains limited.

objectiveTo examine the relationship between total therapy dose and language outcomes, and to explore the influence of sex, recovery phase, and aphasia type.

methodsA longitudinal pre-post study was conducted with 20 adults with aphasia who received eight weeks of individualized speech-language therapy in three rehabilitation centers in Spain. Language performance was assessed with the Spanish version of the Mississippi Aphasia Screening Test (MASTsp). Statistical analyses included Wilcoxon tests, Spearman correlations, regression models, and non-parametric comparisons.

resultsParticipants showed significant improvement after intervention (p = 0.003). Therapy dose correlated positively with language gains (r = 0.624, p = 0.003), and receiving ≥ 20 h predicted greater improvement (p = 0.019). Sex and aphasia type did not significantly influence outcomes. Recovery phase showed a significant effect, with individuals in the acute and subacute stages improving more than those in the chronic phase (p = 0.046).

conclusionsA minimum of 20 therapy hours over eight weeks appears beneficial for language recovery in post-stroke aphasia. Recovery phase emerged as a relevant factor, while sex and aphasia type showed no measurable impact. These findings contribute practice-based evidence supporting the role of therapy dose in aphasia rehabilitation.

Indexed as

AphasiaIntensityLanguage rehabilitationRecovery phaseSpeech-language therapyStrokeTherapy dose

Identifiers

PMID42822365
PMCPMC13659502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.